Differences between COX-2-specific inhibitors: clinical and economic implications

Am J Manag Care. 2002 Oct;8(15 Suppl):S428-30.
No abstract available

Publication types

  • Comment
  • Comparative Study
  • Review

MeSH terms

  • Aged
  • Blood Pressure / drug effects
  • Cardiovascular Diseases / chemically induced
  • Celecoxib
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / economics
  • Cyclooxygenase Inhibitors / therapeutic use
  • Drug Costs
  • Female
  • Humans
  • Isoenzymes / antagonists & inhibitors
  • Lactones / adverse effects*
  • Lactones / economics
  • Lactones / therapeutic use
  • Male
  • Membrane Proteins
  • Prostaglandin-Endoperoxide Synthases
  • Pyrazoles
  • Risk Factors
  • Sulfonamides / adverse effects*
  • Sulfonamides / economics
  • Sulfonamides / therapeutic use
  • Sulfones
  • United States

Substances

  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Lactones
  • Membrane Proteins
  • Pyrazoles
  • Sulfonamides
  • Sulfones
  • rofecoxib
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Celecoxib